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Lung surfactant secretion is a highly regulated process. Our previous studies have shown that VAMP-
2 is essential for surfactant secretion. In the present study we investigated the role of miR-206 in
surfactant secretion through VAMP-2. VAMP-2 was conﬁrmed to be a target of miR-206 by
30-untranslational region (30-UTR) luciferase assay. Mutations in the predicated miR-206 binding
sites reduced the binding of miR-206 to the 30-UTR of VAMP-2. miR-206 decreased the expression
of VAMP-2 protein and decreased the lung surfactant secretion in alveolar type II cells. In conclu-
sion, miR-206 regulates lung surfactant secretion by limiting the availability of VAMP-2 protein.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
MicroRNAs (miRNAs) are evolutionarily conserved small RNAs,
typically 19–23 nucleotides, in eukaryotes. miRNAs are ﬁrst tran-
scribed as primary miRNAs (pri-miRNA) by RNA polymerase II
and further processed by RNase III, Drosha, to a precursor miRNA
(pre-miRNA). The pre-miRNA is transported into the cytoplasm
by exportin 5, where it forms mature miRNA through the cleavage
by Dicer. One of the mature miRNA strands incorporates into the
RNA inducing silencing complex. This complex binds 30-untrans-
lated region (30-UTR) of a target mRNA to cause protein translation
repression or mRNA degradation. A miRNA can target multiple pro-
teins and thus regulate various physiological and pathological pro-
cesses [1].
Lung alveoli are the basic unit for gas exchange. They are lined
by squamous alveolar epithelial type I and cuboidal type II cells.
Alveolar type II cells synthesize, store and secrete a surface active
lipid-rich substance called lung surfactant. The lung surfactant is
stored in the lamellar bodies. Following stimulation of type II cells,
the lamellar bodies fuse with plasma membrane, releasing their
contents into the alveolar lumen. The secreted surfactant reduces
the surface tension and prevents the collapse of lung alveoli. Lungsurfactant deﬁciency leads to infant/neonatal respiratory distress
syndrome [2].
A number of signaling cascades are important in lung surfactant
secretion [2]. Lipid rafts and their constituent proteins also regu-
late surfactant secretion [3–5]. Our previous studies have demon-
strated that the soluble N-ethylmaleimide-sensitive fusion
protein attachment protein receptors (SNARE), SNAP-23 and syn-
taxin 2 [6], VAMP-2 [7], and other SNARE associated proteins
including NSF and a-SNAP [8] are involved in surfactant secretion.
Furthermore, Annexin A2 mediates the fusion of lamellar bodies
with the plasma membrane by directly interacting with SNAP-23
[9]. We have previously shown that miR-375 and miR-150 modu-
late surfactant secretion by altering cytoskeleton reorganization in
type II cells [10] and targeting purinergic ion-channel receptor
(P2X7R) [11], respectively. However, the miRNAs targeting SNARE
proteins in alveolar type II cells are unknown. In the present study,
we examined the effects of miR-206 on VAMP-2 and lung surfac-
tant secretion.
2. Materials and methods
2.1. Reagents
Fetal bovine serum (FBS), trypsin-EDTA, Dulbecco’s modiﬁed
Eagle’s medium (DMEM), Opti-MEM, non-essential amino acids,
ligase for cloning, pENTR plasmid, and Lipofectamine 2000 were
purchased from Invitrogen Life Technologies (Carlsbad, CA).
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macia (Arlington Heights, IL). Polyclonal rabbit anti-VAMP-2 and
anti-VAMP-8 antibody were from Synaptic System (Goettingen,
Germany). Polyclonal rabbit anti-b-actin, horse serum and prote-
ase inhibitor cocktail were from Sigma (St. Louis, MO). Horseradish
peroxidase-conjugated goat anti-rabbit IgG was from BioRad Labo-
ratories (Hercules, CA). Restriction enzymes were from New Eng-
land Biolab (Ipswich, MA) unless mentioned. Luciferase reporter
plasmid, pGL3 (ﬁreﬂy luciferase) and passive lysis buffer were pur-
chased from Promega (Madison, WI). Poly A polymerase and 18S
rRNA primers were from Ambion (Austin, TX). The minElute reac-
tion cleanup kit was from Qiagen (Valencia, CA).2.2. Cell culture
HEK 293A cells and A549 cells were cultured at 37 C in DMEM
supplemented with 10% FBS and 1% non-essential amino acids.
Media were changed on alternate days. Cells were sub-cultured
every 3 days. PC12 cells were cultured in DMEM with 10% horse
serum and 5% FBS. Media were changed every 3 days, and cells
were sub-cultured every week.2.3. Construction of miRNA overexpression plasmids and adenoviral
vectors
The miRNA overexpression vectors (pENTR-miRNA) contained
the CMV promoter, followed by an enhanced green ﬂorescent pro-
tein (EGFP) tag, a mature miRNA with ﬂanking sequences
(0.5 kb), and the SV40 polyA terminal sequence. The miRNAs
were ampliﬁed from human genomic DNA and inserted into the
pENTR vector through Xho I and EcoR I sites as previously
described [12]. The EGFP expression enabled us to monitor trans-
fection efﬁciency. The empty vector of CMV-driven EGFP was used
as a vector control. The CMV-EGFP-miRNA in pENTR vector was
switched into an adenovirus vector by Gateway technique exactly
as described by the supplier. Adenoviral vectors were then linear-
ized by PacI before they were used to transfect 293A cells. The
virus was ampliﬁed by re-infecting HEK 293A cells. Tilter of virus
was determined in HEK 293A cells. Mature miR-206 is conserved
between rat and human species.2.4. Construction of VAMP-2 reporter vector
The 30-UTR region of VAMP-2 was ampliﬁed from rat cDNA by
using speciﬁc primers (forward: 50-cacctctagaGAGAATTCGGCC
TCTCCCCCACC-30; and reverse: 50gatctagaGATCTAGAAATCTGGATG
CGCCACA-30). Then 30-UTR region (1-1729, numbered after the
stop codon of the VAMP-2 gene) was cloned into the pGL3 vector
through EcoR I and Xba 1 sites. The reporter construct (pFLuc-30-
UTR-VAMP-2) contained the SV40 promoter, a ﬁreﬂy luciferase
reporter gene, the 30-UTR of VAMP-2 and the SV40 poly A terminal
sequence. The binding sites for miR-206 on 30-UTR of VAMP-2 are
conserved among vertebrates.2.5. Dual luciferase assay
Fifty nanogram of miRNA overexpression plasmid, 5 ng of the
reporter construct, pFLuc-30-UTR-VAMP-2, and 1 ng of pRL-TK
Renilla luciferase normalization vector were transfected into HEK
293A cells or A549 cells using Lipofectamine. After being cultured
for 48 h, cells were lysed by the addition of 35 ll of passive lysis
buffer. Seven microliters of lysate were used for determining dual
luciferase activities. The ﬁreﬂy luciferase activity was normalized
against Renilla luciferase activity.2.6. Western blotting
Cells were solubilized in lysis buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1% Triton X-100 and protease inhibitors). Proteins
were separated by 12% of SDS–PAGE, transferred onto nitrocellu-
lose membranes, and immunoblotted with speciﬁc antibodies.
The primary antibodies were used at the following dilutions:
anti-VAMP-2 (1:200), anti-b-actin (1:2000) and anti-VAMP-8
(1:1000). Secondary antibody was used at 1:2000 dilution. Protein
bands were visualized by enhanced chemiluminescence.
2.7. Detection of miRNA expression
miRNA expression was determined as described [13]. Brieﬂy,
1 lg of total RNA was polyadenylated using poly A polymerase.
The RNA product was puriﬁed by mini Elute kit. The RNA was
reverse-transcribed into cDNA using the Poly(T) adapter (GCGAG
CACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN). PCR was
performed using an universal reverse primer (GCGAGCACAGAAT
TAATACGACTCAC) and a miRNA-speciﬁc forward primer (miR-
206: TGGAATGTAAGGAAGTGTGTG; U2: GTTGGAATAGGAGCTTGC
TCCGTCC). PCR conditions were: 95 C for 2 min, 95 C, and 35
cycles of 95 C for 30 s, 35 C for 30 s and 72 C for 30 s. The PCR
products were separated on 2% agarose gel.
2.8. Alveolar type II cells isolation and tissue collection
All of the animal studies were approved by the Institutional Ani-
mal Care and Use Committee at the Oklahoma State University. The
Sprague-Dawley rats (180–200 g)were anesthetizedwith ketamine
and xylazine via intraperitoneal injection. Lung, heart, muscle and
brain were collected for RNA isolation. Alveolar type II cells were
isolated from the rats as previously described [7]. The lungs were
perfused, lavaged, digested with elastase and minced. The cell sus-
pension was ﬁltered through 160-, 37- and 15-lm nylon meshes.
The cells were incubatedwith rat IgG-coated petri dishes to remove
alveolar macrophages. The unattached cells were collected by cen-
trifugation and re-suspended inDMEM. The purity of alveolar type II
cells was more than 90% and viability of cells was more than 95%.
The isolated type II cells were cultured on an air–liquid interface
as described [14]. For lung surfactant secretion, the cells were
labeled with 0.6 lCi of [3H] choline overnight. The cells were
washed and then stimulated with 100 lM ATP and 0.1 lM PMA
for 2 h. The lipids in the media and cells were extracted and [3H]
radioactivities were counted [15]. Surfactant secretion was calcu-
lated as (dpm in medium)/(dpm in medium + dpm in cells)  100%.
2.9. Statistical analysis
Student t-test was used for statistical analysis and P < 0.05 was
considered signiﬁcant.3. Results
3.1. Identiﬁcation of the miRNAs that target VAMP-2
Several computational methods have been developed to predict
the miRNAs that target the 30-UTR of a speciﬁc mRNA. Online soft-
ware tools, Targetscan and Pictar were used to identify miRNAs
that regulate VAMP-2. The tools identiﬁed several miRNA which
could potentially regulate VAMP-2 expression. We then con-
structed miRNA overexpression vectors. The expression of EGFP
and miRNA were under the control of a cytomegalovirus (CMV)
promoter. For conﬁrming the binding of miRNAs to VAMP-2, dual
luciferase assays were employed. The 30-UTR region of VAMP-2
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Fig. 1. Screening of miRNAs that regulate 30-UTR activity of VAMP-2. HEK 293A
cells (A) and A549 cells (B) were transfected with pENTR-miRNA (50 ng), pFLuc-30-
UTR-VAMP-2 (5 ng), and normalization plasmid pRL-TK (1 ng) for 48 h and the dual
luciferase activities assayed. The ﬁreﬂy luciferase activity was normalized with pRL-
TK activity. An empty vector control (VC) was used as a control. The results were
expressed as % of VC. ⁄P < 0.05 vs. VC (n = 3).
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Fig. 3. Expression of miR-206 in tissues and cells. Total RNA was isolated from lung,
heart, skeletal muscle, brain, PC12 cells and alveolar type II cells (TII). All of the
tissues and cells were from rats. The RNA was polyadenylated and reverse-
transcribed. miRNAs were ampliﬁed and separated by agarose gel electrophoresis.
Sample without the addition of poly A polymerase was used as negative control
(NC).
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mid. Overexpression of miR-206 decreased luciferase activity in
HEK 293A cells by 50% (Fig. 1A). We did not observe any signiﬁcant
differences in luciferase activities following the overexpression of
miR-28, miR-367, miR-493, miR-409, miR-185 and miR-34b. Sim-
ilar results were observed in lung epithelial cell line, A549 cells
(Fig. 1B).
3.2. Localization of binding sites for miR-206
We examined whether the effect of miR-206 on VAMP-2
expression was through the binding of miR-206 to the 30-UTR of
VAMP-2 in HEK 293A cells. We mutated the binding sites in theA 
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Fig. 2. Analysis of miRNA binding sites on the 30-UTR of VAMP-2. (A) Binding sites of miR-
in Fig. 1 in HEK 293A (B) and A549 cells (C) with wild-type, mutations in the ﬁrst, secon
means ± SE (n = 3). The results were expressed as% of VC. ⁄P < 0.05 vs. VC (n = 3).30-UTR with three base mutations in its seed sequence (Fig. 2A).
Mutations at the ﬁrst binding site of miR-206 still decreased lucif-
erase activity by 50%. However, when the second binding site was
mutated, miR-206-mediated repression was attenuated (Fig. 2B).
Similar results were obtained when both the binding sites were
mutated. Virus control and the unrelated miRNA, miR-34b did
not affect the luciferase activities of all mutants. Thus, the second
binding site, but not the ﬁrst binding site, was the essential site
for the binding of miR-206 with 30-UTR region of VAMP-2 mRNA.
These results were conﬁrmed in human lung epithelial A549 cells
(Fig. 2C).
3.3. Differential expression of miR-206 in tissues
The expression of miR-206 was studied in various tissue includ-
ing lung, heart, muscle and brain. The expression pattern was also
examined in two diverse secretory cell types i.e., PC12 and alveolar
type II cells. Both PC-12 and alveolar type II cells are secretory cells.
PC-12 is a cell line derived from a transplantable rat pheochromo-
cytoma of adrenal medulla and secretes catecholamines. Alveolar
type II cells isolated from the lung and secrete lung surfactant.
miR-206 was abundantly expressed in the lung, skeletal muscle
and alveolar type II cells (Fig. 3). However, the expression of
miR-206 was minimal in brain and PC12 cells.
3.4. Overexpression of miR-206 leads to repression of VAMP-2
expression
To determine the effect of miR-206 on VAMP-2 expression,
PC12 cell line was used. The cell line was chosen because of 
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206 on 30-UTR region of VAMP-2. (B, C) Luciferase assay was performed as described
d, or both binding sites (Mut1, Mut2, Mut1,2) of 30-UTR reporter. Data shown were
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Fig. 4. Effect of miR-206 overexpression on VAMP-2 expression and surfactant secretion. (A and B) PC12 cells were transduced with an adenovirus expressing a miRNA at a
MOI of 50 for 5 days. The representative images (A) indicating overexpression of miRNAs in PC12 cells using RT-PCR. Western blot analysis (B) for VAMP-2 in PC12
overexpressing miR-206. Blots were reprobed with b-actin as a loading control. (C–E) Type II cells were cultured on an air–liquid interface. The cells were transduced with
miR-206 overexpressing adenovirus (MOI: 100) on day 3. An adenovirus without miR-206 at the same MOI was used as a virus control (VC). The cells were cultured until day
7. The mRNA (C) and protein levels (D) of VAMP-2 were determined by real-time PCR and Western blot, respectively. (E) For measurement of surfactant secretion, cells
cultured for 7 days were stimulated with 100 lM ATP and 0.1 lM PMA for 2 h. The released of [3H]-labeled PC was measured for surfactant secretion. The basal surfactant
secretion was 1.25 ± 0.39. ⁄P < 0.05 vs. VC from 3 cell preparations (Student’s t-test).
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miR-206. PC12 cells were infected with adenovirus overexpressing
miR-206. The RT-PCR conﬁrmed the overexpression of mature
miRNAs following transduction of cells (Fig. 4A). Overexpression
of miR-206 decreased the expression of VAMP-2 protein when
compared to controls (Fig. 4B).
3.5. Overexpression of miR-206 inhibits surfactant secretion
VAMP-2 is one of SNARE partners involved in exocytosis. Since
miR-206 regulated VAMP-2 expression, we investigated the effects
of miR-206 on lung surfactant secretion. Overexpression of miR-
206 in primary alveolar type II cells did not affect the expression
of VAMP-2 mRNA (Fig. 4C). However, the VAMP-2 protein was
reduced (Fig. 4D). Virus control did not affect the expression of
VAMP-2. The miR-206 did not affect expression of VAMP-8. Fur-
thermore, the overexpression of miR-206 signiﬁcantly inhibited
surfactant secretion (Fig. 4E).
4. Discussion
Lung surfactant secretion is regulated by many proteins includ-
ing SNAREs. We have previously shown that miR-375 and miR-150
regulate surfactant secretion by altering cytoskeleton organization
and by targeting P2X7 receptors, respectively [10,11]. In the pres-
ent study we identiﬁed miR-206 as another miRNA that regulates
surfactant secretion through directly targeting VAMP-2.
Several studies have demonstrated that miRNAs have various
roles in exocytosis. miR-375 has been reported to reduce insulin
secretion by targeting myotropin [16]. miR-9 inhibits glucose- or
potassium-elicited insulin secretion by increasing Granuphilin/
Slp4 level through the reduction of Onecut-2 transcription factor
[17]. miR-124 and miR-96 also modulate insulin secretion [18].
miR-142-3p increases FceRI-mediated degranulation from mast
cells [19]. A number of miRNAs directly target SNAREs. For exam-
ple, syntaxin-1a has been conﬁrmed as a direct target of miR-29a
[20]. miR-153 targets SNAP-25 and thus regulates neurotransmis-
sion [21].
Our studies revealed that miR-206 was abundantly expressed in
the lung, especially in alveolar type II cells. Our results are in con-formity with previous reports [22,23]. Our current studies support
a role of miR-206 in lung surfactant secretion since the overexpres-
sion of miR-206 reduced the lung surfactant secretion. This effect is
likely through VAMP-2 because miR-206 down-regulated the
expression of VAMP-2 protein in alveolar type II cells. However,
miR-206 did not decrease the expression of VAMP-2 mRNA, sug-
gesting that miR-206 regulates VAMP-2 expression post-transcrip-
tionally. Since VAMP-2 is localized on the lung lamellar bodies [7],
the miR-206-mediated decrease in VAMP-2 protein could limit the
availability of VAMP-2 for the formation of SNARE complex, a pre-
requisite for membrane fusion, thus suggesting that miR-206 plays
a key role in lung surfactant secretion.
Targetscan search did not ﬁnd any conserved miR-206 binding
sites on the 30-UTR of SNAP-23, syntaxin 2, NSF and a-SNAP. How-
ever, one poorly conserved binding site of miR-206 was found in
the NSF 3-UTR. Thus, it is possible that miR-206 also targets NSF
or other proteins involved in lung surfactant secretion.
miR-206 plays various roles in several organs and cells. In the
lung, miR-206 is down-regulated in bronchopulmonary dysplasia
(BPD) and is associated with the development of BPD [24]. Interest-
ingly, miR-206 is also reduced in the hypoxic lungs and contributes
to pulmonary hypertension [25]. miR-206 inhibits hypertrophy
and differentiation of myogenic cells by targeting histone deacetyl-
ase 4 [26,27] and also regulates muscle regeneration via Hmgb3
[28]. miR-206 represses lipogenesis in hepatocytes and enhances
cholesterol efﬂux in human macrophages via controlling liver X
receptor a [29,30]. miR-206 slows the progression of amyotrophic
lateral sclerosis, a neurodegenerative diseases [31] and contributes
to the escalation of voluntary alcohol consumption by inhibiting
BDNF [32]. The current ﬁnding of miR-206 regulation of lung
surfactant secretion adds an expanding list of new functions of
miR-206.
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